Form 4: Evommune CFO Kyle Carver Receives Stock Option Grant

Evommune, Inc. Chief Financial Officer Kyle Carver was granted 98,946 employee stock options with an exercise price of $26.77.

Summary

• Chief Financial Officer Kyle Carver received a grant of 98,946 employee stock options.
• The options have an exercise price of $26.77 per share.
• The grant date for these options is April 16, 2026.
• The options are set to expire on April 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these stock options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $26.77 exercise price.

Future Outlook

The options vest over a four-year period, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives are standard practice in the biotechnology sector to incentivize long-term retention and performance alignment.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard industry practices for executive compensation in public biotech companies.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first 25% of the option grant on April 16, 2027.

Key Dates

Keywords

Evommune, EVMN, Form 4, Insider Trading, Stock Options, Executive Compensation